Advances in the treatment of graft-versus-host disease with immunomodulatory cells
- 1 March 2021
- journal article
- review article
- Published by Elsevier in International Immunopharmacology
- Vol. 92, 107349
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81803538)
- National Natural Science Foundation of China (U1803129)
- National Natural Science Foundation of China (81973332)
This publication has 112 references indexed in Scilit:
- Cell-autonomous role of TGFβ and IL-2 receptors in CD4+ and CD8+ inducible regulatory T-cell generation during GVHDBlood, 2012
- Instability of Foxp3 Expression Limits the Ability of Induced Regulatory T Cells to Mitigate Graft versus Host DiseaseClinical Cancer Research, 2011
- Interleukin-6 Modulates Graft-versus-Host Responses after Experimental Allogeneic Bone Marrow TransplantationClinical Cancer Research, 2011
- NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effectsBlood, 2010
- Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell doseBlood, 2009
- Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host diseaseBlood, 2009
- DC activated via dectin‐1 convert Treg into IL‐17 producersEuropean Journal of Immunology, 2008
- TGF-β-induced Foxp3 inhibits TH17 cell differentiation by antagonizing RORγt functionNature, 2008
- Induction of FOXP3 expression in naive human CD4+FOXP3− T cells by T-cell receptor stimulation is transforming growth factor-β–dependent but does not confer a regulatory phenotypeBlood, 2007
- Activation-associated phenotype of CD3+ T cells in acute graft-versus-host diseaseClinical and Experimental Immunology, 2006